About Relay Therapeutics
Industry:
TechBio
Founded:
2016
Founders:
Sanjiv Patel, Matt Jacobson, Dorothea Shaw
Status:
Public (NASDAQ: RLAY)
Funding & Growth
Total Raised:
$700M+
Valuation:
$2B+ market cap
Stage:
Public
Key Investors:
D.E. Shaw
GV
a16z
✓ Pros
- • Cutting-edge computational drug discovery
- • D.E. Shaw research heritage
- • Cambridge, MA location
- • Strong scientific culture
- • Well-funded
✗ Cons
- • Clinical-stage risk
- • Stock volatility
- • High technical bar
- • Competitive hiring